Mas, Luis

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

Gómez, H., Mas, L., Casanova, L., Pen, D. L., Santillana, S., Valdivia, S., Otero, J., Rodriguez, W., Carracedo, C., & Vallejos, C. (1998) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentNeutropenia and Cancer Infections

Cited by 155